This company has been acquired
STSA Stock Overview
Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Satsuma Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.10 |
| 52 Week High | US$8.08 |
| 52 Week Low | US$0.59 |
| Beta | 0.10 |
| 1 Month Change | 3.77% |
| 3 Month Change | 19.59% |
| 1 Year Change | -67.46% |
| 3 Year Change | -95.92% |
| 5 Year Change | n/a |
| Change since IPO | -93.49% |
Recent News & Updates
Recent updates
Can Satsuma Pharmaceuticals (NASDAQ:STSA) Afford To Invest In Growth?
Feb 15
Will Satsuma Pharmaceuticals (NASDAQ:STSA) Spend Its Cash Wisely?
Sep 02Here's Why We're Watching Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn Situation
May 13Satsuma Pharmaceuticals: Sizing Up This One Trick Pony
Nov 07Do Institutions Own Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Shares?
Jan 26Shareholder Returns
| STSA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.8% | -0.9% | 1.6% |
| 1Y | -67.5% | -9.5% | 11.7% |
Return vs Industry: STSA underperformed the US Pharmaceuticals industry which returned 2% over the past year.
Return vs Market: STSA underperformed the US Market which returned 5% over the past year.
Price Volatility
| STSA volatility | |
|---|---|
| STSA Average Weekly Movement | 20.0% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: STSA's share price has been volatile over the past 3 months.
Volatility Over Time: STSA's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 25 | John Kollins | www.satsumarx.com |
Satsuma Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops novel therapeutic products for the acute treatment of migraines. The company’s product candidature includes STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Satsuma Pharmaceuticals, Inc. Fundamentals Summary
| STSA fundamental statistics | |
|---|---|
| Market cap | US$36.47m |
| Earnings (TTM) | -US$64.83m |
| Revenue (TTM) | n/a |
Is STSA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| STSA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$64.83m |
| Earnings | -US$64.83m |
Last Reported Earnings
Mar 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.96 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did STSA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/06/09 23:27 |
| End of Day Share Price | 2023/06/07 00:00 |
| Earnings | 2023/03/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Satsuma Pharmaceuticals, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yifan Ye | CLSA |
| Evan Seigerman | Credit Suisse |
| Michael DiFiore | Evercore ISI |